Oral administration of Astragalus membranaceus inhibits the development of DNFB-induced dermatitis in NC/Nga mice

Biological and Pharmaceutical Bulletin

Volumn 30, Issue 8, 2007, Pages 1468-1471

  Lee, Su Jin ^a   Oh, Seung Geun ^a   Seo, Sang Wan ^b   Ahn, Hyun Jong ^a   Geum, Dongho ^c   Cho, Jeong Je ^a   Park, Cheung Seog ^a  

^a Kyung Hee University Hospital   (South Korea)

^b Wonkwang University   (South Korea)

^c Korea University College of Medicine   (South Korea)

Author keywords

2,4 dinitrofluorobenzene (DNFB); Astragalus membranaceus; Atopic dermatitis; NC Nga mice

Indexed keywords

1 FLUORO 2,4 DINITROBENZENE; ASTRAGALUS MEMBRANACEUS EXTRACT; GAMMA INTERFERON; IMMUNOGLOBULIN E; INTERLEUKIN 4; PREDNISOLONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOPIC DERMATITIS; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; DRUG SYNTHESIS; EAR; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDERMIS; FEMALE; INFLAMMATORY CELL; LYMPH NODE; MOUSE; MOUSE STRAIN; NONHUMAN; PROTEIN BLOOD LEVEL; SKIN DEFECT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ASTRAGALUS MEMBRANACEUS; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DERMATITIS, ATOPIC; DINITROFLUOROBENZENE; EAR, EXTERNAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOGLOBULIN E; INTERFERON TYPE II; INTERLEUKIN-4; MICE; MICE, INBRED STRAINS; PREDNISOLONE; SKIN;

EID: 34548026805     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.30.1468     Document Type: Article

References (18)

1. Miyauchi-Hashimoto H., Okamoto H., Sugihara A., Horio T., Photodermatol. Photoimmunol. Photomed., 21, 125-130 (2005).
2. Shiohara T., Hayakawa J., Mizukawa Y., J. Dermatol. Sci., 36, 1-9 (2004).
3. Tomimori Y., Tanaka Y., Goto M., Fukuda Y., J. Invest. Dermatol., 124, 119-124 (2005).
4. Dearman R. J., Kimber I., Immunology, 101, 442-451 (2000).
5. Takeshita K., Tamasaki T., Akira S., Gantner F., Bacon K. B., Int. Immunol., 16, 685-695 (2004).
6. Shao B. M., Xu W., Dai H., Tu P., Li Z., Gao X. M., Biochem. Biophys. Res. Commun., 320, 1103-1111 (2004).
7. Yang Z. G., Sun H. X., Fang W. H., Vaccine, 24, 5196-5203 (2005).
8. Kang H., Ahn K. S., Cho C., Bae H. S., Biol. Pharm. Bull., 27, 1946-1950 (2004).
9. Kobayashi H., Mizuno N., Kutsuna H., Teramae H., Ueoku S., Onoyama J., Yamanaka K., Fujita N., Ishii M., Drugs Exp. Clin. Res., 29, 81-84 (2003).
10. Suzuki T., Takano I., Nagai F., Fujitani T., Ushiyama K., Okubo T., Seto J., Ikeda S., Kano I., Biol. Pharm. Bull., 11, 1180-1184 (1999).
11. Ishimitsu R., Nishimura H., Kawauci H., Kawakita T., Yoshikai Y., Int. Immunopharmacol., 1, 857-865 (2001).
12. Gao X. K., Fuseda K., Shibata T., Tanaka H., Inagaki N., Nagai H., Evid. Based Complement Alternat Med., 2, 191-199 (2005).
13. Yagi R., Nagai H., Iigo Y., Akimoto T., Arai T., Kubo M., J. Immunol., 168, 2020-2027 (2002).
14. Grewe M., Gyufko K., Schopf E., Krutmann J., Lancet, 343, 25-26 (1994).
15. Werfel T., Morita A., Grewe M., Renz H., Wahn U., Krutmann J., Kapp A., J. Invest. Dermatol., 107, 871-876 (1996).
16. Thepen T., Langeveld-wildschut E. G., Bihari I. C., van Wichen D. F., van Reijsen F. C., Mudde G. C., Bruijnzeel-Koomen C. A., J. Allergy Clin. Immunol., 97, 828-837 (1996).
17. Vestergaard C., Yoneyama H., Murai M., Nakamura K., Tamaki K., Terashima Y., Imai T., Yoshie O., Irimura T., Mizutani H., J. Clin. Invest., 104, 1097-1105 (1999).
18. Josephine E. H., Dean J. N., Neil R. K., Rebecca J. D., Ian K., Kebin Park B., Chem. Res. Toxicol., 18, 375-381 (2005).